Építés alatt – nem éles oldal
Belépés
Toborzás még nem indultFázis nélkül

Long-Axial Field of View (LAFOV) [18F]FDG PET/CT Imaging in Large Vessel Vasculitis (LVV): Protocol Optimisation Study.

A legfontosabb adatok

Ki végzi
Imperial College London
Hol
Egyesült Királyság3 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toborzás még nem indult
Résztvevők
18 fő, tervezett
Kezdés
2026. dec. 1.
Várható befejezés
2028. jan. 1.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • [18F]FDG Long-Axial Field of View (LAFOV)-PET/CT
  • CT Angiogram
  • MR Angiogram
A regiszteradat frissítve
2026. október 16.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults newly diagnosed with large vessel vasculitis, an inflammation of the body's main arteries. It also takes a small number of healthy volunteers. Both groups get whole-body PET/CT scans.

Életkor
18 years and older. Healthy volunteers: three aged 18 to under 50, and three aged 50 or older.
Nem
All sexes
A betegség stádiuma
Patients: newly diagnosed large vessel vasculitis, by the 2022 ACR/EULAR criteria or by clear findings on standard imaging. WHO performance status 0-2, meaning able to care for yourself.
Korábbi kezelés
Patients cannot join if they started steroids more than 7 days before the scan tracer is given. Healthy volunteers cannot ever have taken steroids, blood pressure medicine or antipsychotic medicine.
Biomarker vagy leletérték
Patients with a history of kidney problems, kidney transplant or diabetes need an eGFR (kidney function test) of 30 (mL/min/1.73m2) or more within 3 months of the scan.

A részvétel fő kizáró okai

  • Pregnant or breastfeeding
  • Fear of closed spaces, or unable to lie through the scan
  • Patients: allergy to iodine contrast dye, or poorly controlled diabetes with blood sugar >11mmol/L (198 mg/dL)
  • Healthy volunteers: smoking history, weight of 75Kg (165 lb (75 kg)) or more, or kidney disease, diabetes, atrial fibrillation, migraines, rheumatoid arthritis or SLE
  • Healthy volunteers: any scan with radiation in the last 12 months, or cannot have MRI or gadolinium contrast

A regiszter feltételei, szó szerint

Mind a 32 feltétel megnézéseKevesebb

Ki vehet részt

  • ≥18 years of age
  • Newly diagnosed LVV (based on the 2022 American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR) classification criteria or from a definite diagnosis of LVV on standard of care imaging)
  • WHO performance status 0-2
  • The subject is able and willing to comply with study procedures and signed and dated informed consent is obtained
  • eGFR of ≥30 (mL/min/1.73m2) within 3 months of [18F]FDG injection in subjects who have a history of renal impairment, renal disease, renal transplant or diabetes
  • Three subjects ≥18 years of age that are also < 50 years old and three subjects ≥50 years of age
  • WHO performance status 0-2
  • The subject is able and willing to comply with study procedures and signed and dated informed consent is obtained

Ki nem vehet részt

  • Commencement of steroids > 7 days prior to administration of the radiotracer
  • Historic or current prescription of the following medications:
  • Any blood pressure medication
  • Any antipsychotic medication
  • Steroids
  • Weight of ≥75Kg (in order to keep the radiation dose <10mSV for HV)
  • Participants that have undergone any imaging investigation that exposes them to radiation within the previous 12 months
  • History of allergy to iodinated contrast
  • Known allergy to gadolinium-based contrast agents
  • History of smoking
  • History or current diagnosis of the following medical conditions:
  • Renal impairment, renal disease, renal transplant or diabetes mellitus
  • Evidence of any significant medical condition which, in the opinion of the Investigator, makes it undesirable for the HV to participate in the trial
  • Poorly controlled diabetic with a blood glucose >11mmol/L
  • Evidence of a significant medical condition or laboratory finding which, in the opinion of the Investigator, makes it undesirable for the patient to participate in the trial
  • The subject is pregnant or lactating
  • Participants with claustrophobia or who are unable to comfortably tolerate the scanning procedure
  • The subject is pregnant or lactating
  • Participants with claustrophobia or who are unable to comfortably tolerate the scanning procedure
  • Participants with any contra-indication to MRI
  • Atrial Fibrillation
  • Migraines
  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus (SLE)

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Large vessel vasculitis (LVV) is an autoimmune inflammatory disorder affecting the major arteries of the body. The diagnosis and monitoring this condition can be challenging, as patients often present with symptoms that are unclear, and the diagnostic criteria currently used are varied. Accurate diagnosis is essential because it helps to tailor the treatment to each patient. Some treatments, such as steroids and immunosuppressive medications, can have significant side effects, so they need to be used carefully and only when truly needed.

A teljes eredeti leírásKevesebb

An [18F]FDG Positron Emission Tomography/Computed Tomography (PET/CT) involves the injection of a small amount of radiolabelled sugar, which assesses glucose metabolism within the body. [18F]FDG PET/CT is already used by the NHS to detect inflammation within the vessel walls and diagnose LVV. Current diagnostic criteria for LVV largely rely on visual assessment by a radiologist. This approach therefore has limitations and may not fully capture changes in the levels of inflammation over time.

A new generation of scanners, known as Long Axial Field-of-View (LAFOV)-PET/CT or Total Body PET, are currently transforming what is possible in the field of medical imaging. These LAFOV-PET/CT scanners have new digital detectors that are more sensitive, produce sharper images, and can scan the entire body rapidly. This offers several potential advantages for patients with LVV, including the clearer detection of vessel wall inflammation, the ability to administer lower doses of the radiolabelled sugar ([18F]FDG), and the ability to take repeated pictures over time to measure subtle changes in blood flow and inflammation. Patients receiving a routine NHS [18F]FDG PET/CT scan for LVV are typically scanned 60 minutes after injection of the radiotracer using a standard PET/CT. Another benefit of LAFOV-PET/CT scanners is their ability to assess the amount of the radiolabelled sugar taken up by the whole body almost as soon as it is injected which could give important additional information.

As part of the LAVA-FLOW study we are planning to combine LAFOV-PET/CT with a CT Angiogram (CTA) in patients with LVV. A CTA is a scan that shows doctors what your blood vessels look like. It involves the injection of a dye into a vein that makes your blood vessels visible, highlighting vessel wall inflammation and vessel wall narrowing. This combination of LAFOV-PET/CT and CTA therefore has the potential to give a much more detailed picture of LVV than is achievable using current methods.

The LAVA-FLOW study therefore aims to develop a standardised protocol to be used in different hospital centres across the UK for the imaging of LVV using LAFOV-PET/CT. We also hope that the results of this particular study could lead to further larger studies with the potential to update the diagnostic criteria and improve the monitoring of this condition.

A vizsgálat 2 csoportja

  • LVV Patients: [18F]LAFOV-PET/CT & CT AngiogramA vizsgált kezelés

    Kezelés: [18F]FDG Long-Axial Field of View (LAFOV)-PET/CT és CT Angiogram

  • Healthy Volunteers: [18F]LAFOV-PET/CT & MR AngiogramA vizsgált kezelés

    Kezelés: [18F]FDG Long-Axial Field of View (LAFOV)-PET/CT és MR Angiogram

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
A regiszteradat frissítve
2026. október 16.